KDR and cancer: The selection of these agents is therefore driven by their mechanistic diversity, tumor-selective targeting, and alignment with three critical hallmarks of cancer: sustained proliferative signaling (FGFR2b), loss of adhesion and polarity (CLDN18.2), and angiogenesis (VEGFR2).